Black Rock Inc. Dyadic International Inc Transaction History

Black Rock Inc.

$4.23 Trillion
Q1 2024

A detailed history of Black Rock Inc. transactions in Dyadic International Inc stock. As of the latest transaction made, Black Rock Inc. holds 247,462 shares of DYAI stock, worth $539,467. This represents 0.0% of its overall portfolio holdings.

Number of Shares

247,462

Previous 248,614 0.46%

Holding current value

$539,467

Previous $400,000 3.25%

% of portfolio

0.0%

Previous 0.0%

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 10, 2024	SELL	$1.29 - $1.67 $1,486 - $1,923	-1,152 Reduced 0.46%	247,462 $413,000
Q4 2023 Feb 13, 2024	SELL	$1.52 - $2.04 $875 - $1,175	-576 Reduced 0.23%	248,614 $400,000
Q3 2023 Nov 13, 2023	SELL	$1.71 - $2.08 $22,766 - $27,693	-13,314 Reduced 5.07%	249,190 $478,000
Q2 2023 Aug 11, 2023	BUY	$1.56 - $2.38 $7,141 - $10,895	4,578 Added 1.77%	262,504 $506,000
Q1 2023 May 12, 2023	BUY	$1.25 - $1.86 $1,693 - $2,520	1,355 Added 0.53%	257,926 $459,000

Q4 2022 Feb 13, 2023	BUY	$1.18 - $2.29 $355 - $689	301 Added 0.12%	256,571 $315,000
Q3 2022 Nov 14, 2022	BUY	$1.72 - $3.42 $1,713 - $3,406	996 Added 0.39%	256,270 $490,000
Q2 2022 Aug 12, 2022	BUY	$1.85 - $3.22 $8,482 - $14,763	4,585 Added 1.83%	255,274 $778,000
Q1 2022 May 12, 2022	SELL	$3.01 - $4.81 $8,355 - $13,352	-2,776 Reduced 1.1%	250,689 $754,000
Q4 2021 Feb 10, 2022	BUY	$3.36 - $5.34 $6,111 - $9,713	1,819 Added 0.72%	253,465 $1.15 Million
Q3 2021 Nov 09, 2021	SELL	$3.3 - $6.49 $24,420 - $48,026	-7,400 Reduced 2.86%	251,646 $1.4 Million
Q2 2021 Aug 11, 2021	BUY	$3.35 - $5.67 $867,804 - $1.47 Million	259,046 New	259,046 $929,000

Others Institutions Holding DYAI

# of Institutions

Shares Held

4.52M

Call Options Held

1.2K

Put Options Held

View Full List

About DYADIC INTERNATIONAL INC

Ticker DYAI
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 28,423,100
Market Cap $62M
Description
Dyadic International, Inc., a biotechnology platform company, develops, produces, and sells enzymes and other proteins in the United States. The company utilizes its patented and proprietary C1 platform and other technologies to conduct research, development, and commercial activities for the development and manufacturing of human and animal vac...

More about DYAI

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Black Rock Inc., based on Form 13F filings with the SEC.

News

Stay updated on Black Rock Inc. with notifications on news.

Account